Thryv Therapeutics is developing selective inhibitors of Serum Glucocorticoid Inducible Kinase (SGK1) to treat Congenital Long QT Syndrome, atrial fibrillation, and heart failure. Their precision medicine approach aims to improve patient outcomes by targeting the underlying mechanisms of these arrhythmias.
Funding
$16.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for cardiac arrhythmias like Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure often lack precision, failing to address the underlying genetic or molecular causes and leading to suboptimal patient outcomes. Existing therapies may also have significant side effects or limited efficacy in certain patient populations.
Solution
Thryv Therapeutics is developing selective inhibitors of Serum Glucocorticoid Inducible Kinase (SGK1) as a precision medicine approach to treat cardiac arrhythmias. By targeting SGK1, a kinase implicated in the pathophysiology of these conditions, Thryv aims to develop therapies that address the root cause of the arrhythmia, leading to improved efficacy and reduced side effects. Their lead compounds are designed to selectively inhibit SGK1, modulating ion channel function and restoring normal cardiac rhythm. Thryv's approach includes identifying patient subgroups most likely to benefit from SGK1 inhibition through genetic and biomarker analysis, ensuring targeted treatment and improved clinical outcomes. The company has multiple SGK1 inhibitors in preclinical and clinical development, with ongoing studies evaluating their safety and efficacy in LQTS, atrial fibrillation, and heart failure.
Target Audience
The primary target audience includes patients with Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure, as well as the physicians and specialists who treat these conditions, particularly electrophysiologists and cardiologists.
Features
- Selective SGK1 inhibitors designed for enhanced target engagement and minimal off-target effects
- Precision medicine approach using genetic and biomarker analysis to identify optimal patient populations
- Clinical programs in Congenital Long QT Syndrome (LQTS), atrial fibrillation, and heart failure
- Oral bioavailability for convenient administration
- Potential for disease-modifying effects by targeting the underlying mechanisms of arrhythmias
- Ongoing Phase 1 clinical trials to assess safety and pharmacokinetics
- Preclinical data demonstrating efficacy in models of drug-induced QT prolongation and atrial fibrillation
- Development of multiple novel SGK1 inhibitors with distinct pharmacological profiles